Clinical trials
Observational trials in Kuwait
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
99 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 2 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 9 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 6 |
| 2020 | 7 |
| 2021 | 13 |
| 2022 | 8 |
| 2023 | 8 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 67 |
| Recruiting | 12 |
| Unknown status | 10 |
| Active, not recruiting | 5 |
| Terminated | 4 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 14 |
| Bayer | 10 |
| Sanofi | 6 |
| Hoffmann-La Roche | 5 |
| AbbVie | 4 |
| Dasman Diabetes Institute | 4 |
| Medtronic | 4 |
| Ministry of Health, Kuwait | 4 |
| Boushahri Clinic Medical Center | 3 |
| Genzyme, a Sanofi Company | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 7 |
| Diabetes Mellitus | 5 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Arrhythmias, Cardiac | 3 |
| Asthma | 3 |
| Atrial Fibrillation | 3 |
| Bradycardia | 3 |
| Carcinoma, Hepatocellular | 3 |
| Diabetes Mellitus, Type 1 | 3 |
| Heart Failure | 3 |
Trials
Showing 26 to 50 of 99. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.